Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

NCT03940196 is registered in ClinicalTrials.gov with NovoCure Ltd. as lead sponsor.

NCT NCT03940196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03940196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Lead sponsor
NovoCure Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 22, 2019
Completion date
May 18, 2023
Enrollment
540 (actual)
Sites
119

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer